Clinical Trials
16 trialsNCT01555892 2026-03-02
GRALE
Baylor College of Medicine
Phase 1 Recruiting
NCT03602157 2026-01-06
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT00710892 2025-07-11
CASPALLO
Baylor College of Medicine
Phase 1 Active not recruiting
NCT01494103 2025-07-11
DOTTI
Baylor College of Medicine
Phase 1 Active not recruiting
NCT02663297 2025-05-15
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03939585 2024-12-05
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
Case Comprehensive Cancer Center
Phase 1 Withdrawn
NCT02973113 2021-07-21
PREVALE
Baylor College of Medicine
Phase 1 Completed
NCT03601819 2021-01-22
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders
University of Michigan Rogel Cancer Center
Phase 1 Terminated
NCT00093704 2020-07-31
Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT01447056 2020-02-07
MALTED
Baylor College of Medicine
Phase 1 Completed
NCT00058604 2020-01-18
EUCLID
Baylor College of Medicine
Phase 1 Completed
NCT02057445 2017-12-22
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
New York Medical College
Phase 1 Completed
NCT00968461 2013-04-15
Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00087009 2013-03-19
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 1 Terminated
NCT01147991 2012-02-28
Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer
Cancer Research UK
Phase 1 Completed
NCT00646139 2011-03-02
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
Roswell Park Cancer Institute
Phase 1 Completed